{
  "metadata": {
    "case_id": 85,
    "model": "Gemini-3-Pro",
    "timestamp": "2025-11-29T19:19:56.310492",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/85_NCT02740231.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Gemini-3-Pro/85_Gemini-3-Pro.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 4,
      "pred_count": 4,
      "similarity_matrix": [
        [
          0.25,
          0.18,
          0.2,
          0.82
        ],
        [
          0.78,
          0.82,
          0.86,
          0.18
        ],
        [
          0.82,
          0.78,
          0.82,
          0.2
        ],
        [
          0.93,
          0.82,
          0.82,
          0.25
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 3,
          "score": 0.82,
          "status": "matched",
          "ref_item": {
            "label": "Reference product",
            "type": "ACTIVE_COMPARATOR",
            "description": "Hylan G-F 20",
            "interventionNames": [
              "Device: Reference product intra-articular injection"
            ]
          },
          "pred_item": {
            "label": "Reference group",
            "type": "ACTIVE_COMPARATOR",
            "description": "Patients received one dose of the reference treatment (hylan G-F 20) in 6 ml volume.",
            "interventionNames": [
              "Hylan G-F 20"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 2,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "label": "JTA-004 50 (2 ml)",
            "type": "EXPERIMENTAL",
            "description": "Sodium hyaluronate, plasma proteins and clonidine",
            "interventionNames": [
              "Drug: JTA-004 intra-articular injection"
            ]
          },
          "pred_item": {
            "label": "JTA-200/4",
            "type": "EXPERIMENTAL",
            "description": "Patients received one dose of JTA-004 formulation containing 200 μg clonidine and 40 mg hyaluronic acid in 4 ml volume.",
            "interventionNames": [
              "JTA-004 (JTA-200/4)"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 1,
          "score": 0.78,
          "status": "matched",
          "ref_item": {
            "label": "JTA-004 50 (4 ml)",
            "type": "EXPERIMENTAL",
            "description": "Sodium hyaluronate, plasma proteins and clonidine",
            "interventionNames": [
              "Drug: JTA-004 intra-articular injection"
            ]
          },
          "pred_item": {
            "label": "JTA-200/2",
            "type": "EXPERIMENTAL",
            "description": "Patients received one dose of JTA-004 formulation containing 200 μg clonidine and 20 mg hyaluronic acid in 2 ml volume.",
            "interventionNames": [
              "JTA-004 (JTA-200/2)"
            ]
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 0,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "label": "JTA-004 100 (2 ml)",
            "type": "EXPERIMENTAL",
            "description": "Sodium hyaluronate, plasma proteins and clonidine",
            "interventionNames": [
              "Drug: JTA-004 intra-articular injection"
            ]
          },
          "pred_item": {
            "label": "JTA-100/2",
            "type": "EXPERIMENTAL",
            "description": "Patients received one dose of JTA-004 formulation containing 100 μg clonidine and 20 mg hyaluronic acid in 2 ml volume.",
            "interventionNames": [
              "JTA-004 (JTA-100/2)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 4,
      "similarity_matrix": [
        [
          0.92,
          0.9,
          0.94,
          0.78
        ],
        [
          0.65,
          0.4,
          0.28,
          0.73
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 2,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "JTA-004 intra-articular injection",
            "description": "Each patient will undergo a single injection of JTA-004 into the knee joint",
            "armGroupLabels": [
              "JTA-004 100 (2 ml)",
              "JTA-004 50 (2 ml)",
              "JTA-004 50 (4 ml)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "JTA-004 (JTA-200/4)",
            "description": "Enhanced protein solution derived from human plasma containing 50 μg/ml clonidine (200 μg total) and 10 mg/ml hyaluronic acid (40 mg total) in a 4 ml volume. Provided as a freeze-dried powder reconstituted with sterile water before single intra-articular injection.",
            "armGroupLabels": [
              "JTA-200/4"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 3,
          "score": 0.73,
          "status": "matched",
          "ref_item": {
            "type": "DEVICE",
            "name": "Reference product intra-articular injection",
            "description": "Each patient will undergo a single injection of Reference product into the knee joint",
            "armGroupLabels": [
              "Reference product"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Hylan G-F 20",
            "description": "Sterile viscoelastic solution provided in a ready-to-use syringe (6 ml) containing 48 mg sodium hyaluronate (Synvisc-One). Administered as a single intra-articular injection.",
            "armGroupLabels": [
              "Reference group"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.96
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "Change From Baseline in WOMAC VA3.1 Pain Subscale Score at Month 6",
            "description": "The primary endpoint is the Western Ontario McMaster universities (WOMAC®) VA3.1 Pain Subscale (subscale A): the individual changes in WOMAC® VA3.1 Pain Subscale Score between Baseline and Month 6 were calculated and compared by analysis of covariance (ANCOVA), adjusted for baseline value, to the Reference group.\n\nResults are expressed as \"adjusted mean\" based on the model used for group comparison.\n\nWOMAC Osteoarthritis Index is a tri-dimensional, self-administered, patient-centred health status questionnaire for knee disease severity ans osteonecrosis symptoms. The WOMAC® Index Pain Subscale (VAS format) was used. The VAS score was determined by measuring in millimetres from the left-hand end of the line to the point that the patient marks (0-100 mm) for 5 questions. Results are summed and normalized on a 100 mm scale: 0 represents no knee pain and 100 extreme knee pain.",
            "timeFrame": "Baseline and 6 months"
          },
          "pred_item": {
            "measure": "Change in WOMAC Pain Subscale Score",
            "description": "Adjusted mean change from baseline in Western Ontario McMaster Universities (WOMAC) Pain Subscale Score. Scores were determined using self-administered questionnaires with a 0-100 mm Visual Analogue Scale (VAS), where 0 mm represents no symptoms and 100 mm represents extreme symptoms.",
            "timeFrame": "Month 3 (Stage 1 selection), Month 6 (Stage 2 efficacy)"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 4,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.72,
          0.9
        ],
        [
          0.82,
          0.48
        ],
        [
          0.9,
          0.78
        ],
        [
          0.98,
          0.68
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 1,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "WOMAC® Pain Subscale at Month 3",
            "description": "The primary endpoint is the Western Ontario McMaster universities (WOMAC®) VA3.1 Pain Subscale (subscale A): the individual changes in WOMAC® VA3.1 Pain Subscale Score between Baseline and Month 3 were calculated and compared by analysis of covariance (ANCOVA), adjusted for baseline value, to the Reference group.\n\nResults are expressed as \"adjusted mean\" based on the model used for group comparison.\n\nWOMAC Osteoarthritis Index is a tri-dimensional, self-administered, patient-centred health status questionnaire for knee disease severity ans osteonecrosis symptoms. The WOMAC® Index Pain Subscale (VAS format) was used. The VAS score was determined by measuring in millimetres from the left-hand end of the line to the point that the patient marks (0-100 mm) for 5 questions. Results are summed and normalized on a 100 mm scale: 0 represents no knee pain and 100 extreme knee pain.",
            "timeFrame": "Baseline and 3 months"
          },
          "pred_item": {
            "measure": "WOMAC Pain Subscale Score",
            "description": "Assessment of the Pain Subscale specifically as a secondary endpoint for the final analysis.",
            "timeFrame": "Month 3"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "WOMAC® Total Score Over Time",
            "description": "The Western Ontario McMaster universities (WOMAC®) VA3.1 Total Score was used: the individual changes in WOMAC VA3.1 Total Score between Baseline and 2 weeks were calculated and compared by Mixed-Effect Model for Repeated Measurements, adjusted for baseline value, to the Reference group.\n\nResults are expressed as \"adjusted mean\" based on the model used for group comparison.\n\nWOMAC Osteoarthritis Index is a tri-dimensional, self-administered, patient-centred health status questionnaire for knee disease severity and osteonecrosis symptoms. The Total score (VAS format) was determined by measuring in millimetres from the left hand end of the line to the point that the patient marks (0-100 mm) for the pain (5 questions), stiffness (2 questions), and physical function (17 questions). Results are normalized on a 0-100 mm scale format. A higher score represents a higher degree of k",
            "timeFrame": "Baseline and 2 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "WOMAC® Total Score Over Time",
            "description": "The Western Ontario McMaster universities (WOMAC®) VA3.1 Total Score was used: the individual changes in WOMAC VA3.1 Total Score between Baseline and Month 3 were calculated and compared by Mixed-Effect Model for Repeated Measurements, adjusted for baseline value, to the Reference group.\n\nResults are expressed as \"adjusted mean\" based on the model used for group comparison.\n\nWOMAC Osteoarthritis Index is a tri-dimensional, self-administered, patient-centred health status questionnaire for knee disease severity ans osteonecrosis symptoms. The Total score (VAS format) was determined by measuring in millimetres from the left hand end of the line to the point that the patient marks (0-100 mm) for the pain (5 questions), stiffness (2 questions), and physical function (17 questions). Results are normalized on a 0-100 mm scale format. A higher score represents a higher degree of knee disease severity.",
            "timeFrame": "Baseline and 3 months"
          },
          "pred_item": null
        },
        {
          "ref_idx": 3,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "measure": "WOMAC® Total Score Over Time",
            "description": "The Western Ontario McMaster universities (WOMAC®) VA3.1 Total Score was used: the individual changes in WOMAC VA3.1 Total Score between Baseline and Month 6 were calculated and compared by Mixed-Effect Model for Repeated Measurements, adjusted for baseline value, to the Reference group.\n\nResults are expressed as \"adjusted mean\" based on the model used for group comparison.\n\nWOMAC Osteoarthritis Index is a tri-dimensional, self-administered, patient-centred health status questionnaire for knee disease severity ans osteonecrosis symptoms.The Total score (VAS format) was determined by measuring in millimetres from the left hand end of the line to the point that the patient marks (0-100 mm) for the pain (5 questions), stiffness (2 questions), and physical function (17 questions). Results are normalized on a 0-100 mm scale format. A higher score represents a higher degree of knee disease severity.",
            "timeFrame": "Baseline and 6 months"
          },
          "pred_item": {
            "measure": "WOMAC Total Score",
            "description": "Assessment of the total score from the Western Ontario McMaster Universities Osteoarthritis Index, evaluating pain, stiffness, and knee function.",
            "timeFrame": "Up to Month 6"
          }
        }
      ]
    }
  ]
}